通过急性治疗优化预防发作性偏头痛向慢性偏头痛的进展。
Preventing the Progression of Episodic Migraine to Chronic Migraine with Acute Treatment Optimization.
机构信息
Westport Headache Institute, Westport, CT, USA.
Yale School of Medicine, New Haven, CT, USA.
出版信息
Curr Pain Headache Rep. 2022 Mar;26(3):253-258. doi: 10.1007/s11916-022-01022-0. Epub 2022 Feb 8.
PURPOSE OF REVIEW
To evaluate the evidence regarding acute migraine treatment optimization to prevent the progression of episodic migraine to chronic migraine. This review also provides a summary of evidence-based acute migraine treatments and how to tailor a regimen based on an individual patient's needs.
RECENT FINDINGS
Several acute migraine treatments have been food and drug administration (FDA)-approved since 2020. This review summarizes pain freedom data at 2 h for these medications and devices and examines the classic acute migraine treatments. This review presents the existing data about acute treatment optimization and its preventive role in the progression of episodic migraine to chronic migraine. We present updated clinical trial efficacy endpoints from the American Headache Society (AHS) and the FDA and review the evidence for acute migraine treatments currently available in clinical practice.
目的综述
评估急性偏头痛治疗优化以预防发作性偏头痛向慢性偏头痛进展的证据。本综述还总结了基于循证的急性偏头痛治疗方法，以及如何根据个体患者的需求制定治疗方案。
最新发现
自 2020 年以来，有几种急性偏头痛治疗方法已获得美国食品和药物管理局（FDA）批准。本综述总结了这些药物和设备在 2 小时时的止痛效果数据，并检查了经典的急性偏头痛治疗方法。本综述介绍了急性治疗优化的现有数据及其在发作性偏头痛向慢性偏头痛进展中的预防作用。我们提出了美国头痛协会（AHS）和 FDA 的更新临床试验疗效终点，并回顾了目前临床实践中可用的急性偏头痛治疗方法的证据。
Zotero 插件